Our mission is simple.  Beat cancer to improve the lives of patients and their families.

ApeX Therapeutics is a biotechnology company focused on developing novel compounds to treat cancer.  Our lead drug candidate – APX3330 – targets the treatment of pancreatic cancer and we expect to be in human clinical studies in 2016.  Our experienced team of scientists and researchers is focused on getting there as fast as possible.


Our scientific founder, Dr. Mark R. Kelley is a recognized expert in the area of APE1/Ref-1 biology.
Kelley, our founder and the Chief Scientific Officer, is currently the Betty and Earl Herr Chair in Pediatric Oncology Research and Professor, Departments of Biochemistry & Molecular Biology and Pharmacology & Toxicology,, Indiana University School of Medicine. He is also the Associate Director, Herman B. Wells Center for Pediatric Research and the Associate Director for Basic Science Research at the IU Simon Cancer Center. + read more about the ApeX team

Our science is unique and represents first-in-class therapeutic potential.
Inhibitors of Ref-1 have been shown to broadly affect several factors involved in cancer survival. Apex Therapeutics’ lead molecule, APX3330 has shown dramatic efficacy in numerous pre-clinical cancer models, including pancreatic cancer. ApeX Therapeutics expects to begin clinical trials with APX3330 in cancer patients in 2016.
+ read more about the R&D at ApeX

Our focus is pancreatic cancer, one of the most deadly cancers in the world.
Despite significant progress in the treatment of other cancers, pancreatic cancer is still one of the deadliest types of cancer with poor prognosis and few effective therapies. According to the American Cancer Society, in 2016 almost 50,000 people in the US will be diagnosed with pancreatic cancer and almost 40,000 will die from the disease.
+ Read more about ApeX cancer research